Table of Content

1. Key Insights


2. Report Introduction


3. HPV16+ Cancer Market Overview at a Glance

3.1. Market Share (%) Distribution of HPV16+ Cancer in 2018

3.2. Market Share (%) Distribution of HPV16+ Cancer in 2030


4. Executive Summary of HPV16+ Cancer


5. Disease Background and Overview

5.1. Introduction

5.2. Etiology

5.3. Risk Factors

5.4. Molecular Mechanisms of HPV

5.5. Malignances associated with HPV

5.6. HPV and Cancer Progression

5.7. Diagnosis

5.8. Biomarkers


6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Assumption and Rationale

6.3. 7MM Total Incident Patient Population of HPV induced Cancer

6.4. The United States

6.4.1. Incident Cases of HPV induced Cancer in the US

6.5. EU5

6.5.1. Germany

6.5.1.1. Incident Cases of HPV induced Cancer in Germany

6.5.2. France

6.5.2.1. Incident Cases of HPV induced Cancer in France

6.5.3. Italy

6.5.3.1. Incident Cases of HPV induced Cancer in Italy

6.5.4. Spain

6.5.4.1. Incident Cases of HPV16+ Cancer in Spain

6.5.5. United Kingdom

6.5.5.1. Incident Cases of HPV induced Cancer in the UK

6.6. Japan

6.6.1. Incident Cases of HPV induced Cancer in Japan


7. Treatment and Management

7.1. HPV Vaccines


8. Organizations contributing towards HPV16+ Cancer


9. Patient Journey


10. Case Reports


11. Marketed Products

11.1. Gardasil: Merck

11.1.1. Product Description

11.1.2. Mechanism of action

11.1.3. Regulatory Milestones

11.1.4. Side effects of Gardasil

11.1.5. Product Profile

11.2. Gardasil 9: Merck

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Safety and Efficacy of Gardasil 9

11.2.4. Side effects of Gardasil 9

11.2.5. Product Profile

11.3. Cervarix: GlaxoSmithKline

11.3.1. Product Description

11.3.2. Regulatory Milestones

11.3.3. Safety and Efficacy of Cervarix

11.3.4. Side effects of Cervarix

11.3.5. Product Profile


12. Emerging Therapies

12.1. PDS0101: PDS Biotechnology/Merck

12.1.1. Drug Description

12.1.2. Regulatory Milestones

12.1.3. Clinical Development

12.1.3.1. Clinical Trials Information

12.1.4. Product Profile

12.2. CUE-101: Cue Biopharma/Merck

12.2.1. Drug Description

12.2.2. Regulatory Milestones

12.2.3. Clinical Development

12.2.3.1. Clinical Trials Information

12.2.4. Product Profile

12.3. ISA101b: ISA Pharmaceuticals/Regeneron Pharmaceuticals

12.3.1. Drug Description

12.3.2. Regulatory Milestones

12.3.3. Clinical Development

12.3.3.1. Clinical Trials Information

12.3.4. Product Profile

12.4. VB10.16: Vaccibody AS/Roche

12.4.1. Drug Description

12.4.2. Regulatory Milestones

12.4.3. Clinical Development

12.4.3.1. Clinical Trials Information

12.4.4. Product Profile

12.5. TG4001: Transgene

12.5.1. Drug Description

12.5.2. Regulatory Milestones

12.5.3. Clinical Development

12.5.3.1. Clinical Trials Information

12.5.4. Product Profile

12.6. VGX-3100: Innovio Pharma

12.6.1. Drug Description

12.6.2. Regulatory Milestones

12.6.3. Clinical Development

12.6.3.1. Clinical Trials Information

12.6.4. Safety and Efficacy

12.6.5. Product Profile

12.7. HB-201: Hookipa Pharma

12.7.1. Drug Description

12.7.2. Clinical Development

12.7.2.1. Clinical Trials Information

12.7.3. Product Profile

12.8. HB-202: Hookipa Pharma

12.8.1. Drug Description

12.8.2. Clinical Development

12.8.2.1. Clinical Trials Information

12.8.3. Product Profile

12.9. UCPVax: Roche Pharma AG/Invectys

12.9.1. Drug Description

12.9.2. Clinical Development

12.9.2.1. Clinical Trials Information

12.9.3. Product Profile

12.10. BNT113: BioNTech

12.10.1. Drug Description

12.10.2. Regulatory Milestones

12.10.3. Clinical Development

12.10.3.1. Clinical Trials Information

12.10.4. Product Profile

12.11. ADXS 11-001: Advaxis, Inc.

12.11.1. Drug Description

12.11.2. Regulatory Milestones

12.11.3. Clinical Development

12.11.3.1. Clinical Trials Information

12.11.4. Safety and Efficacy

12.11.5. Product Profile

12.12. M7824: Merck

12.12.1. Drug Description

12.12.2. Regulatory Milestones

12.12.3. Clinical Development

12.12.3.1. Clinical Trials Information

12.12.4. Product Profile

12.13. PRGN-2009: Precigen

12.13.1. Drug Description

12.13.2. Clinical Development

12.13.2.1. Clinical Trials Information

12.13.3. Product Profile


13. HPV16+ Cancer: Seven Major Market Analysis

13.1. Key Findings

13.2. Market Size of HPV16+ Cancer in the 7MM


14. Market Outlook

14.1. United States Market Size

14.1.1. Total Market Size of HPV16+ Cancer in the US

14.1.2. Market Size of HPV16+ Cancer by therapies in the US

14.2. EU-5

14.2.1. Germany

14.2.1.1. Total Market size of HPV16+ Cancer in Germany

14.2.1.2. Market Size of HPV16+ Cancer by therapies in Germany

14.2.2. France

14.2.2.1. Total Market size of HPV16+ Cancer in France

14.2.2.2. Market Size of HPV16+ Cancer by therapies in France

14.2.3. Italy

14.2.3.1. Total Market size of HPV16+ Cancer in Italy

14.2.3.2. Market Size of HPV16+ Cancer by therapies in Italy

14.2.4. Spain

14.2.4.1. Total Market size of HPV16+ Cancer in Spain

14.2.4.2. Market Size of HPV16+ Cancer by therapies in Spain

14.2.5. United Kingdom

14.2.5.1. Total Market size of HPV16+ Cancer in the UK

14.2.5.2. Market Size of HPV16+ Cancer by therapies in the UK

14.3. Japan

14.3.1. Total Market size of HPV16+ Cancer in Japan

14.3.2. Market Size of HPV16+ Cancer by Therapies in Japan

15. Market Drivers

16. Market Barriers

17. SWOT Analysis

18. Unmet Needs

19. Market Access and Reimbursement

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight



List of Figures

Figure 1: Incident cases of HPV induced Cancer in the 7MM (2018–2030)

Figure 2: Incident Cases of HPV induced Cancer in the US (2018–2030)

Figure 3: Incident Cases of HPV induced Cancer in Germany (2018–2030)

Figure 4: Incident Cases of HPV induced Cancer in France (2018–2030)

Figure 5: Incident Cases of HPV induced Cancer in Italy (2018–2030)

Figure 6: Incident Cases of HPV induced Cancer in Spain (2018–2030)

Figure 7: Incident Cases of HPV induced Cancer in the UK (2018–2030)

Figure 8: Incident Cases of HPV induced Cancer in Japan (2018–2030)

Figure 9: 7 Major Market Size of HPV16+ Cancer in USD Million (2018–2030)

Figure 10: The US Market Size of HPV16+ Cancer by Class, USD Million (2018–2030)

Figure 11: The US Market Size of HPV16+ Cancer by therapies in USD Million (2018–2030)

Figure 12: Germany Market Size of HPV16+ Cancer, USD Million (2018–2030)

Figure 13: Germany Market Size of HPV16+ Cancer by therapies in USD Million (2018–2030)

Figure 14: France Market Size of HPV16+ Cancer, USD Million (2018–2030)

Figure 15: France Market Size of HPV16+ Cancer by therapies in USD Million (2018–2030)

Figure 16: Italy Market Size of HPV16+ Cancer, USD Million (2018–2030)

Figure 17: Italy Market Size of HPV16+ Cancer by therapies in USD Million

Figure 18: Spain Market Size of HPV16+ Cancer, USD Million (2018–2030)

Figure 19: Spain Market Size of HPV16+ Cancer by therapies in USD Million (2018–2030)

Figure 20: The UK Market Size of HPV16+ Cancer, USD Million (2018–2030)

Figure 21: The UK Market Size of HPV16+ Cancer by therapies in USD Million (2018–2030)

Figure 22: Japan Market Size of HPV16+ Cancer, USD Million (2018–2030)

Figure 23: Japan Market Size of HPV16+ Cancer by Therapies in USD Million(2018–2030)

List of Tables

Table 1: Summary of HPV16+ Cancer, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Incident Cases of HPV16+ Cancer in the 7MM (2018–2030)

Table 3: Incident Cases of HPV induced Cancer in the US (2018–2030)

Table 4: Incident Cases of HPV induced Cancer in Germany (2018–2030)

Table 5: Incident Cases of HPV induced Cancer in France (2018–2030)

Table 6: Incident Cases of HPV induced Cancer in Italy (2018–2030)

Table 7: Incident Cases of HPV16+ Cancer in Spain (2018–2030)

Table 8: Incident Cases of HPV induced Cancer in the UK (2018–2030)

Table 9: Incident Cases of HPV induced Cancer in Japan (2018–2030)

Table 10: Organizations Contributing Toward the Fight Against HPV16+ Cancer

Table 11: PDS0101, Clinical Trial Description, 2021

Table 12: CUE-101, Clinical Trial Description, 2021

Table 13: VT-1161, Clinical Trial Description, 2021

Table 14: VB10.16, Clinical Trial Description, 2021

Table 15: TG4001, Clinical Trial Description, 2021

Table 16: VGX-3100, Clinical Trial Description, 2021

Table 17: HB-201, Clinical Trial Description, 2021

Table 18: HB-202, Clinical Trial Description, 2021

Table 19: UCPVax, Clinical Trial Description, 2021

Table 20: BNT113, Clinical Trial Description, 2021

Table 21: ADXS11-001, Clinical Trial Description, 2021

Table 22: M7824, Clinical Trial Description, 2021

Table 23: PGRN-2009, Clinical Trial Description, 2021

Table 24: 7 Major Market Size of HPV16+ Cancerin USD Million (2018–2030)

Table 25: The US Market Size of HPV16+ Cancer in USD Million (2018–2030)

Table 26: The US Market Size of HPV16+ Cancer by therapies in USD Million (2018–2030)

Table 27: Germany Market Size of HPV16+ Cancer in USD Million (2018–2030)

Table 28: Germany Market Size of HPV16+ Cancer by therapies in USD Million (2018–2030)

Table 29: France Market Size of HPV16+ Cancer in USD Million (2018–2030)

Table 30: France Market Size of HPV16+ Cancer by therapies in USD Million (2018–2030)

Table 31: Italy Market Size of HPV16+ Cancer in USD Million (2018–2030)

Table 32: Italy Market Size of HPV16+ Cancer by therapies in USD Million (2018–2030)

Table 33: Spain Market Size of HPV16+ Cancer in USD Million (2018–2030)

Table 34: Spain Market Size of HPV16+ Cancer by therapies in USD Million (2018–2030)

Table 35: The UK Market Size of HPV16+ Cancer in USD Million (2018–2030)

Table 36: The UK Market Size of HPV16+ Cancer by therapies in USD Million (2018–2030)

Table 37: Japan Market Size of HPV16+ Cancer in USD Million (2018–2030)

Table 38: Japan Market Size of HPV16+ Cancer by Therapies in USD Million (2018–2030)